Academic Journal
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study.
| العنوان: | Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. |
|---|---|
| المؤلفون: | SIRAGUSA, Sergio, MALATO, Alessandra, SACCULLO, Giorgia, TUTTOLOMONDO, Antonino, PINTO, Antonio, PEPE, Ilenia, CASUCCIO, Alessandra, ABBADESSA, Vincenzo, LICATA, Giuseppe, RINI, Giovam Battista, DI FEDE, Gaetana, Iorio, A, Di Ianni, M, Caracciolo, C, Lo Coco, L, Raso, S, SANTORO, Marco, Guarneri, F, Mariani, G |
| المساهمون: | Siragusa, S, Malato, A, Saccullo, G, Iorio, A, Di Ianni, M, Caracciolo, C, Lo Coco, L, Raso, S, Santoro, M, Guarneri, F, Tuttolomondo, A, Pinto, A, Pepe, I, Casuccio, A, Abbadessa, V, Licata, G, Rini, GB, Mariani, G, Di Fede, G |
| بيانات النشر: | John Wiley & Sons Incorporated |
| سنة النشر: | 2011 |
| المجموعة: | IRIS Università degli Studi di Palermo |
| مصطلحات موضوعية: | deep vein thrombosis (DVT), vitamin K antagonist (VKA) therapy, Residual vein thrombosis, Settore MED/15 - Malattie Del Sangue |
| الوصف: | The safest duration of anticoagulation after idiopathic deep vein thrombosis (DVT) is unknown. We conducted a prospective study to assess the optimal duration of vitamin K antagonist (VKA) therapy considering the risk of recurrence of thrombosis according to residual vein thrombosis (RVT). Patients with a first unprovoked DVT were evaluated for the presence of RVT after 3 months of VKA administration; those without RVT suspended VKA, while those with RVT continued oral anticoagulation for up to 2 years. Recurrent thrombosis and/or bleeding events were recorded during treatment (RVT group) and 1 year after VKA withdrawal (both groups). Among 409 patients evaluated for unprovoked DVT, 33.2% (136 of 409 patients) did not have RVT and VKA was stopped. The remaining 273 (66.8%) patients with RVT received anticoagulants for an additional 21 months; during this period of treatment, recurrent venous thromboembolism and major bleeding occurred in 4.7% and 1.1% of patients, respectively. After VKA suspension, the rates of recurrent thrombotic events were 1.4% and 10.4% in the no-RVT and RVT groups, respectively (relative risk = 7.4; 95% confidence interval = 4.9-9.9). These results indicate that in patients without RVT, a short period of treatment with a VKA is sufficient; in those with persistent RVT, treatment extended to 2 years substantially reduces, but does not eliminate, the risk of recurrent thrombosis. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/21953853; info:eu-repo/semantics/altIdentifier/wos/WOS:000296604800002; volume:86; issue:11; firstpage:914; lastpage:917; numberofpages:4; journal:AMERICAN JOURNAL OF HEMATOLOGY; http://hdl.handle.net/10447/78133 |
| DOI: | 10.1002/ajh.22156 |
| الاتاحة: | http://hdl.handle.net/10447/78133 https://doi.org/10.1002/ajh.22156 |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.45DFE989 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1002/ajh.22156 |
|---|